Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Nov;17(33):4447-4456.
doi: 10.2217/fon-2021-0597. Epub 2021 Aug 3.

Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

Cengiz Karacin  1   2 , Tulay Eren  3 , Esra Zeynelgil  3 , Goksen Inanc Imamoglu  3 , Mustafa Altinbas  3 , Ibrahim Karadag  2 , Fatma Bugdayci Basal  2 , Irem Bilgetekin  2 , Osman Sutcuoglu  4 , Ozan Yazici  4 , Nuriye Ozdemir  4 , Ahmet Ozet  4 , Yesim Yildiz  5 , Selin Akturk Esen  6 , Gokhan Ucar  6 , Dogan Uncu  6 , Bedia Dinc  7 , Musa Baris Aykan  8 , İsmail Erturk  8 , Nuri Karadurmus  8 , Burak Civelek  9 , İsmail Çelik  10 , Yakup Ergun  11 , Mutlu Dogan  2 , Omur Berna Oksuzoglu  2
Affiliations
Observational Study

Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

Cengiz Karacin et al. Future Oncol. 2021 Nov.

Abstract

Aim: To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Methods: This multicenter, prospective, observational study was conducted with 47 patients receiving active systemic therapy for cancer. CoronaVac was administered as two doses (3 μg/day) on days 0 and 28. Antibody level higher than 1 IU/ml was defined as 'immunogenicity.' Results: The immunogenicity rate was 63.8% (30/47) in the entire patient group, 59.5% (25/42) in those receiving at least one cytotoxic drug and 100% (five of five) in those receiving monoclonal antibody or immunotherapy alone. Age was an independent predictive factor for immunogenicity (odds ratio: 0.830; p = 0.043). Conclusion: More than half of cancer patients receiving active systemic therapy developed immunogenicity.

Keywords: COVID-19; cancer; chemotherapy; immunogenicity; immunotherapy; monoclonal antibody; safety; tumors; vaccine.

PubMed Disclaimer

References

    1. WHO coronavirus (COVID-19) dashboard (2021). https://covid19.who.int/
    1. Yekedüz E, Utkan G, Ürün Y. A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19. Eur. J. Cancer 141, 92–104 (2020). - PMC - PubMed
    1. Karacin C, Acar R, Bal O et al. “Swords and Shields” against COVID-19 for patients with cancer at “clean” and “pandemic” hospitals: are we ready for the second wave? Support. Care Cancer 29(8), 4587–4593 (2021). - PMC - PubMed
    1. Akagunduz B, Ozer M, Karacin C, Atcı MM, Yıldırım HC, Unver E. Impact of coronaphobia on treatment and follow-up compliance of cancer patients. Future Oncol. 17(20), 2621–2629 (2021). - PubMed
    1. Garassino MC, Vyas M, de Vries EGE, Kanesvaran R, Giuliani R, Peters S. The ESMO call to action on COVID-19 vaccinations and patients with cancer: vaccinate. Monitor. Educate. Ann. Oncol. 32(5), 579–581 (2021). - PMC - PubMed

    2. • Discusses the importance of COVID-19 vaccines in patients with cancer.

Publication types

MeSH terms